Abstract LB-107: Targeting CDK7-dependent transcriptional addiction with novel, orally available small molecule inhibitor shows efficacy in pancreatic cancer models
Trason Thode(Translational Genomics Research Institute), Sunil Sharma(Translational Genomics Research Institute), Hariprasad Vankayalapti(Translational Genomics Research Institute), Alexis Weston(Translational Genomics Research Institute), Mohan R. Kaadige(Translational Genomics Research Institute), Raffaella Soldi(Banner Health), Zhaoliang Li(Translational Genomics Research Institute)
Cited by 3
Related Papers
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
|Prostate Cancer and Prostatic Diseases|2016|47
MondoA-Mlx Transcriptional Activity Is Limited by mTOR-MondoA Interaction
|Molecular and Cellular Biology|2014|41
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells
|Oncotarget|2018|27
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial Carcinoma
|Molecular Cancer Therapeutics|2018|24